Zobrazeno 1 - 10
of 24
pro vyhledávání: ''
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Serguei Kozlov, Ming Yi, Suman Mukhopadhyay, William E. Burgan, Dwight V. Nissley, Debanjan Goswami, Pavan P. Adiseshaiah, Frank McCormick, Theresa Guerin
Publikováno v:
Cancer research, vol 80, iss 8
Pancreatic cancer is a disease with limited therapeutic options. Resistance to chemotherapies poses a significant clinical challenge for patients with pancreatic cancer and contributes to a high rate of recurrence. Oncogenic KRAS, a critical driver o
Autor:
Takashi Kojima, Masahiro Yasunaga, Kenji Hirotani, Yasutoshi Kuboki, Toshihiko Doi, Takashi Kagari, Yoshikatsu Koga, Naoyuki Maeda, Yasuhiro Matsumura, Mayumi Yamauchi, Shigehiro Koganemaru
Publikováno v:
Molecular Cancer Therapeutics. 18:2043-2050
HER3 is overexpressed in several cancers, including colorectal cancer. Although therapies with anti-HER3 antibodies have been investigated, significant clinical benefits have not been reported. U3-1402 is a novel HER3-antibody–drug conjugate (ADC)
Autor:
Carmen Maria Barnes, Ellen Filvaroff, Shi Tao, Mehnaz Malek, Gordon L. Bray, Winfried Elis, Yumin Dai, Konstantinos Mavrommatis, Lixin Qiao, Terri Jones, Ida Aronchik, Beebe Lisa, Matt Labenski
Publikováno v:
Molecular Cancer Research. 17:642-654
As a critical signaling node, ERK1/2 are attractive drug targets, particularly in tumors driven by activation of the MAPK pathway. Utility of targeting the MAPK pathway has been demonstrated by clinical responses to inhibitors of MEK1/2 or RAF kinase
Autor:
Rebecca J. Nagy, Paul A. VanderLaan, Bryan C. Ulrich, Stephen Wang, Magda Bahcall, Giulia Costanza Leonardi, Emily S. Chambers, Man Xu, Marzia Capelletti, Jihyun Choi, Richard B. Lanman, Mark M. Awad, Amanda J. Redig, Hideo Baba, Paul Kirschmeier, Yu Imamura, Elena Ivanova, Frederick H. Wilson, Lynette M. Sholl, Cloud P. Paweletz, Masayuki Watanabe, Sangeetha Palakurthi, Pasi A. Jänne, Mizuki Nishino, Daniel B. Costa
Publikováno v:
Clinical Cancer Research. 24:5963-5976
Purpose: MET inhibitors can be effective therapies in patients with MET exon 14 (METex14) mutant non–small cell lung cancer (NSCLC). However, long-term efficacy is limited by the development of drug resistance. In this study, we characterize acquir
Autor:
Ilaria Conti, Sheng-Bin Peng, James J. Starling, Igor Mochalkin, Henry James Robert, Sean Buchanan, Robert D. Van Horn, Lysiane Huber, Gregory D. Plowman, Swee Seong Wong, Youyan Zhang, Vipin Yadav, Yong Gang Yue, Shih-Hsun Chen, Tinggui Yin
Publikováno v:
Cancer Discovery. 6:300-315
We have identified previously undiscovered BRAF in-frame deletions near the αC-helix region of the kinase domain in pancreatic, lung, ovarian, and thyroid cancers. These deletions are mutually exclusive with KRAS mutations and occur in 4.21% of KRAS
Autor:
Luigi Formisano, Erika Martinelli, Matilde Lambiase, Francesca Fenizia, Roberto Bianco, Floriana Morgillo, Fortunato Ciardiello, Giulia Martini, Donata Vitagliano, Teresa Troiani, Claudia Cardone, Nicola Normanno, Davide Ciardiello, Stefania Napolitano
Publikováno v:
Clinical Cancer Research. 21:4153-4164
Purpose: The use of cetuximab in the treatment of metastatic colorectal cancer is limited by development of resistance. Experimental Design: We have investigated in three models of highly epidermal growth factor receptor (EGFR)–dependent colorectal
Autor:
Catherine Anne Eberlein, Garry Beran, Eiki Ichihara, William Pao, Zhongwu Lai, Henry Brown, Daniel Stetson, Paul R. Fisher, Jonathan R. Dry, Claire Barnes, Ambar Ahmed, Paul D. Smith, Miika Ahdesmaki, Paula J. Spitzler, Catherine B. Meador, Darren Cross, Elizabeth L. Christey O'Brien, Sarah Ross, Katherine Al-Kadhimi, Kenneth S. Thress, Laura E. Ratcliffe, Brian Dougherty, Aleksandra Markovets
Publikováno v:
Cancer Research. 75:2489-2500
Resistance to targeted EGFR inhibitors is likely to develop in EGFR-mutant lung cancers. Early identification of innate or acquired resistance mechanisms to these agents is essential to direct development of future therapies. We describe the detectio
Autor:
Noelia Ferruz, Israel Cañadas, Alba Dalmases, Joaquim Bellmunt, Marta Salido, Federica Di Nicolantonio, Giorgio Corti, Alberto Bardelli, Mar Iglesias, Juan Sánchez, Giovanni Crisafulli, Elena Gavilán, Sandra Misale, Alejandro Martínez, Joan Albanell, Clara Montagut, Iria Gonzalez, Gianni De Fabritiis, Beatriz Bellosillo, Mariangela Russo, Giulia Siravegna, Sabrina Arena, Ana Rovira, Sebastijan Hobor, Luca Lazzari
Publikováno v:
Clinical Cancer Research. 21:2157-2166
Purpose: Patients with colorectal cancer who respond to the anti-EGFR antibody cetuximab often develop resistance within several months of initiating therapy. To design new lines of treatment, the molecular landscape of resistant tumors must be ascer
Publikováno v:
Molecular Cancer Research. 13:659-669
KRAS mutations are frequently detected in human colorectal cancer and contribute to de novo apoptosis resistance and ultimately therapeutic failure. To overcome KRAS-mediated apoptosis resistance, the irreversible proteasome inhibitor, carfilzomib, w